This CPB has been revised to state that bortezomib is considered medically necessary for Waldenstrom's macroglobulinemia and systemic light-chain amyloidosis. These policy revisions are supported by guidelines from the National Comprehensive Cancer Network. This CPB is revised to state that bortezomib is considered experimental and investigational for diffuse large B-cell lymphoma.